Please login to the form below
Zinplava
This page shows the latest Zinplava news and features for those working in and with pharma, biotech and healthcare.
Finch’s microbiota drug for C. diff gets FDA breakthrough status
Other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) – which works by neutralising toxins secreted by the bacterium – and prophylactic
Latest news
-
Microbiome specialist Rebiotix chalks up C. diff trial success
Meanwhile, other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) - which works by neutralising toxins secreted by the bacterium - and
-
After delay, Merck gets US approval for serious infection drug
In June, an FDA advisory committee voted by 10 to 5 with one abstention that Zinplava (bezlotoxumab) is effective for preventing the recurrence of C. ... Merck stresses that Zinplava should not be used alone as it is not an antibacterial drug.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
